SBMFF (Sino Biopharmaceutical) Total Receivables: $1,117 Mil (As of Dec. 2025)


SBMFF Sino Biopharmaceutical Ltd SBMFF
62 GF Score
Price $0.59
GF Value $0.67
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sino Biopharmaceutical Total Receivables?

Sino Biopharmaceutical SBMFF -1.48% 62 Total Receivables is $1,117 Mil as of Dec. 2025. GuruFocus rates SBMFF with a GF Score™ of 62/100 and a GF Value™ of $0.67 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Sino Biopharmaceutical's Total Receivables for the quarter that ended in Dec. 2025 was $1,117 Mil.

Sino Biopharmaceutical Total Receivables Related Terms

Sino Biopharmaceutical Total Receivables Historical Data

* Premium members only.

The historical data trend for Sino Biopharmaceutical's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sino Biopharmaceutical Total Receivables Chart

Sino Biopharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 869.37 891.99 868.13 933.99 1,117.28

Sino Biopharmaceutical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 868.13 1,406.74 933.99 1,656.34 1,117.28
SBMFF
62GF Score
Sino Biopharmaceutical Ltd SBMFF
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sino Biopharmaceutical Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $1,117 Mil mean?
Sino Biopharmaceutical (SBMFF) has a Total Receivables of $1,117 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Sino Biopharmaceutical and its competitors.
Is Sino Biopharmaceutical's Total Receivables too high?
Sino Biopharmaceutical's current Total Receivables is $1,117 Mil. Overall, Sino Biopharmaceutical has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's Total Receivables compare to VRTX and REGN?
Sino Biopharmaceutical's Total Receivables of $1,117 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Sino Biopharmaceutical and its competitors. Sino Biopharmaceutical's current Total Receivables is $1,117 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (SBMFF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.67, compared to a current price of $0.59 — trading 11.5% below its estimated fair value. The current Total Receivables is $1,117 Mil. Sino Biopharmaceutical's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Sino Biopharmaceutical (SBMFF), the current Total Receivables is $1,117 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sino Biopharmaceutical (SBMFF) Overvalued in 2026?

Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be undervalued. The current stock price of $0.59 is trading 11.5% below its estimated GF Value™ of $0.67. GuruFocus considers Sino Biopharmaceutical to be Modestly Undervalued.

Key valuation signals for SBMFF:

  • Total Receivables: $1,117 Mil
  • GF Value™: $0.67 vs. price of $0.59 (11.5% below fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the SBMFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sino Biopharmaceutical Business Description

Address 1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
62GF Score

Get the complete analysis for SBMFF

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.59
Price
$0.67
GF Value